Recent Finacing
Recent Raise
CrossPoint Therapeutics develops a "Stealth‑Body" Fc‑silencing platform that removes FcγR effector binding while preserving FcRn half‑life, applying it to ADCs, immune‑modulating ADCs, and dendritic‑cell‑activating dual therapies.
